Advances in clinical pharmacology最新文献_第5页

[Critical remarks to the hospital on antifungal chemotherapy]. 【对医院抗真菌化疗的批评意见】。

Advances in clinical pharmacology Pub Date : 1977-01-01

T Wegmann

引用次数: 0

[Clinicopharmacological studies with pindolol following intravenous and oral administration]. 静脉和口服给药后品多洛尔的临床药理学研究。

Advances in clinical pharmacology Pub Date : 1976-01-01

W H Aellig

引用次数: 0

Dissociation of the renin lowering and antihypertensive actions of propranolol. 心得安的解离降肾素和降压作用。

Advances in clinical pharmacology Pub Date : 1976-01-01

S Julius, M Esler, L Hansson, A J Zwiefler

{"title":"Dissociation of the renin lowering and antihypertensive actions of propranolol.","authors":"S Julius, M Esler, L Hansson, A J Zwiefler","doi":"","DOIUrl":"","url":null,"abstract":"Suppression of renin release by beta-adrenoceptor blocking drugs has been advocated as the prime blood pressure lowering mechanism of these agents. The present report casts doubt on this proposition in three ways. In the first study, involving 22 patients with borderline hypertension, patients with elevated plasma renin levels showed normalization of the blood pressure after pharmacological autonomic blockade with intravenous atropine, propranolol and phentolamine, the time course of the pressure fall being such as to exclude suppression of renin release as the antihypertensive mechanism. It is clear that in patients with mild hypertension and high plasma renin levels, the elevation of blood pressure is maintained by a neurogenic mechanism, the elevated plasma renin having no direct role in sustaining the higher blood pressure. In two additional studies involving 21 patients in all with mild to moderately severe essential hypertension, to whom propranolol was administereed by mouth for 1--3 months, two findings were of interest:1) patients with low-renin essential hypertension showed a good antihypertensive response to propranolol, and 2) in some patients a dosedependent dissociation of the renin and blood pressure lowering action of propranolol could be demonstrated. These findings militate against the assumption that propranolol selectively lowers the blood pressure in \"renin-dependent\" hypertension, and strongly suggest that the antihypertensive action of this drug is not mediated by depression of plasma renin activity.","PeriodicalId":75437,"journal":{"name":"Advances in clinical pharmacology","volume":"11 ","pages":"33-41"},"PeriodicalIF":0.0,"publicationDate":"1976-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12212726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Antihypertensive and hemodynamic effects of beta-receptor blockaders with various action spectra]. 不同作用谱β受体阻滞剂的降压和血流动力学作用。

Advances in clinical pharmacology Pub Date : 1976-01-01

G Lohmöller, H Lydtin, E D Frohlich

引用次数: 0

Hemodynamic effects of adrenergic beta-receptor blocking agents. 肾上腺素能受体阻滞剂的血流动力学效应。

Advances in clinical pharmacology Pub Date : 1976-01-01

R Sannerstedt

引用次数: 0

[Management of milder forms of hypertension using new beta-receptor blockaders]. [使用新型受体阻滞剂治疗轻度高血压]。

Advances in clinical pharmacology Pub Date : 1976-01-01

H Pozenel

引用次数: 0

Combination therapy of essential hypertension with pindolol (Visken) and hydralazine. 品多洛尔与肼嗪联合治疗原发性高血压。

Advances in clinical pharmacology Pub Date : 1976-01-01

I Persson

引用次数: 0

[Effect of pindolol (Visken) on blood pressure and plasma renin activity in various forms of hypertension]. pindolol (Visken)对各种高血压患者血压和血浆肾素活性的影响。

Advances in clinical pharmacology Pub Date : 1976-01-01

C Werning, H Vetter

{"title":"[Effect of pindolol (Visken) on blood pressure and plasma renin activity in various forms of hypertension].","authors":"C Werning, H Vetter","doi":"","DOIUrl":"","url":null,"abstract":"1. In 20 of 20 patients (100%) with borderline hypertension Visken normalized the labile blood pressure. The high renin values after stimulation due to orthostasis and saluresis decreased significantly (p less than 0,01). 2. In 3 of 12 patients (25%) with hyporeninemic essential hypertension Visken alone normalized the blood pressure. The low renin values increased to the normal range. 3. In 4 of 18 patients (22%) with normoreninemic essential hypertension Visken normalized the blood pressure. The normal renin values showed a decreasing tendency within the normal range. 4. In 4 of 10 patients (40%) with hyperreninemic essential hypertension Visken normalized the high blood pressure. In 3 of these patients renin decreased distinctly. 5. In 4 of 20 patients (20%) with renal hypertension a therapy with Visken alone normalized the blood pressure. In 3 patients the high renin values decreased to the normal range. 6. In the most other patients of the groups II to V the additional therapy with diuretics and reserpine normalized the blood pressure. In these cases the renin values showed different reactions corresponding to the different effects of betablocking agents, saluretics or reserpine on the plasma renin activity [7]. 7. It is interesting, that Visken not only suppresses high renin values (borderline hypertension [6], hyperreninemic essential hypertension), but also increases low renin values to the normal range in patients with hyporeninemic essential hypertension. Because in essential hypertension the high blood pressure per se may be responsible for the renin suppression [3,4], this increase of renin activity is possibly the consequence of blood pressure reduction, while the decrease of renin activity after Visken may be the cause of blood pressure reduction.","PeriodicalId":75437,"journal":{"name":"Advances in clinical pharmacology","volume":"11 ","pages":"54-60"},"PeriodicalIF":0.0,"publicationDate":"1976-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12212727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Pharmacology of beta blockaders]. [β受体阻滞剂的药理学]。

Advances in clinical pharmacology Pub Date : 1976-01-01

W R Kukovetz, G Pöch

引用次数: 0

The effect of prindolol on plasma noradrenaline, plasma renin and sodium-potassium metabolism in patients with essential hypertension. 普林多洛尔对原发性高血压患者血浆去甲肾上腺素、血浆肾素及钠钾代谢的影响。

Advances in clinical pharmacology Pub Date : 1976-01-01

H M Brecht, E Werner, W Schoeppe

{"title":"The effect of prindolol on plasma noradrenaline, plasma renin and sodium-potassium metabolism in patients with essential hypertension.","authors":"H M Brecht, E Werner, W Schoeppe","doi":"","DOIUrl":"","url":null,"abstract":"The chronic administration of prindolol in patients with essential hypertension resulted in the following: 1) a significant decrease in blood pressure and heart rate (with only the exception of the unchanged diastolic blood pressure after the stimulus of the seven-minute standing period), 2) a significant decrease of plasma noradrenaline concentrativn at rest and under orthostatic conditions, 3) a significant decrease of PRC at rest and an even more pronounced suppression of PRA after the stimulus of upright posture, 4)a significant decrease in total exchangeable sodium and 5) a concomitant significant increase in total body potassium even with an increase in body weight. These findings are not subject to easy interpretation. In particular, we cannot conclude which of the changed parameters plays the initial role in lowering blood pressure. A working hypothesis might presume that beta blocking agents inhibit central and/or peripheral sympathetic nervous activity. The results reduction in plasma renin concentration would in turn lead to a drop in aldosterone secretion rate indicated by the increase in potassium and decrease in sodiummour data would support such a sequence of events.","PeriodicalId":75437,"journal":{"name":"Advances in clinical pharmacology","volume":"11 ","pages":"66-9"},"PeriodicalIF":0.0,"publicationDate":"1976-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12212728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0